Genetic Engineering & Biotechnology News

DON'T MISS OUT! Navigating Quality Control and Release Testing in Cell and Gene Therapy Development Thursday, November 21, 2024 8:00 am PT, 11:00 am ET, 17:00 CET In this November 21st GEN webinar, Audrey Chang and Jianbo Diao will present important considerations for quality control testing for biosafety and product characterization in GMP release and stability studies of novel cell and gene therapies. Register now to join us for this free webinar sponsored by WuXi AppTec: https://hubs.li/Q02XhkxN0 #mRNA

Quotient Sciences Installs GMP Biofoundry-in-a-Box for RNA Production Centillion’s BiaB technology offers continuous flow-based manufacture and encapsulation of RNA, more flexibility with higher productivities at smaller footprints, and enables larger quantities of #RNA drug substance to be split and encapsulated in portions.

Optogenetics May Switch On New Treatments for Epilepsy Using optogenetics, researchers from University of California, San Francisco, University of California, Berkeley, and University of California, Santa Cruz used pulses of light to prevent seizure-like activity in neurons. The researchers used brain tissue that had been removed from #epilepsy patients as part of their treatment. Eventually, they hope the technique will replace surgery to remove the brain tissue where seizures originate, providing a less invasive option for patients whose symptoms cannot be controlled with medication.

Vaccine, ETF Shares Drop as Trump Chooses RFK Jr. for HHS Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s severe criticism of the jabs—whose development Trump’s first administration shepherded through “Operation Warp Speed.” Don't miss Alex Philippidis' latest StockWatch! Moderna., BioNTech SE, Pfizer, Novavax, Emergent BioSolutions, atai Life Sciences, Compass Pathways, Eyenovia, Inc., Nuvectis Pharma, Pulmatrix Inc.

Omics Data Analysis: A Range of Options Data analysis experts share their views on open source software, commercial software, cloud-based platforms, and outsourcing solutions. GEN's Kevin Mayer spoke with Seqera's Evan Floden, PhD, Rami Mehio, from Illumina, Andrew Olson from QIAGEN Digital Insights, Matt Newman from DNAnexus, and Jessica Corrado from Bridge Informatics.

Treehill CEO Sees Positives for Biopharma in Trump’s Re-Election Ali Pashazadeh, the founder, chairman, and CEO of Treehill Partners, a London-based investment firm, discusses the likely effects of Donald Trump’s return to the White House in an exclusive interview with GEN Edge's Alex Philippidis.

Novel Immunotherapy Attacks Glioblastoma from Multiple Angles Researchers at the University of Basel and the Universit?tsspital Basel (USB) have developed an immunotherapy in mice that not only attacks glioblastoma but also turns its microenvironment against it.

Machine Learning Reveals Impact of Microbial Load on Gut Health and Disease "This further confirms the importance of including microbial load in microbiome association studies to avoid false positives or false negatives,” said Suguru Nishijima, PhD, from EMBL.

CAR T-Cells Use SNIPR Technology to Confirm Cancer Targets before Firing University of California, San Francisco researchers developed synthetic intramembrane proteolysis receptors that, when engineered into CAR T-cells sense targets in the surrounding environment to trigger anticancer activity in mice.

LAST CHANCE! Using Oxford Nanopore’s Multi-Omic Sequencing to Optimize Plasmids and Vectors for Cell and Gene In this GEN webinar TODAY, Andrea O'Hara, Ph.D., a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use nanopore sequencing technology to enhance the precision and efficiency of cell and gene therapy programs. Register now to join us for this free webinar sponsored by Oxford Nanopore Technologies: https://hubs.li/Q02WjQpt0 Heather Stark #Omics #DrugDiscovery